| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
36,651,000 |
| Market
Cap: |
665.22(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$15.36 - $28.66 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Quanterix is a life sciences company that has developed digital immunoassay platforms. Co.'s platforms are based on its proprietary digital Simoa detection technology. Co. provides the following three Simoa instruments: HD-X, which is based on Co.'s bead-based technology, and assays run on the HD-X are fully automated; SR-X, which utilizes the same Simoa bead-based technology and assay kits as the HD-X in a compact benchtop form with a range of applications; and SP-X, which is based on Co.'s planar array technology, which allows for multiplexing capabilities for oncology and immunology applications.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
20,200 |
639,331 |
| Total Buy Value |
$0 |
$0 |
$501,978 |
$6,053,841 |
| Total People Bought |
0 |
0 |
1 |
7 |
| Total Buy Transactions |
0 |
0 |
1 |
8 |
| Total Shares Sold |
2,500 |
5,000 |
6,500 |
9,597 |
| Total Sell Value |
$48,970 |
$112,405 |
$145,240 |
$196,398 |
| Total People Sold |
1 |
1 |
1 |
5 |
| Total Sell Transactions |
2 |
4 |
5 |
12 |
| End Date |
2024-03-14 |
2023-12-12 |
2023-06-13 |
2022-06-13 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Roskey Mark T. |
SVP, Commercial & Accelerator |
• – – |
2020-10-01 |
4 |
S |
$34.12 |
$3,139 |
D/D |
(92) |
21,279 |
|
-133% |
|
| Mattoon Dawn |
Sr. VP, Research Products |
• – – |
2020-10-01 |
4 |
S |
$34.12 |
$5,425 |
D/D |
(159) |
31,503 |
|
-133% |
|
| Fry John J |
General Counsel & Secretary |
• – – |
2020-10-01 |
4 |
S |
$34.12 |
$4,880 |
D/D |
(143) |
31,227 |
|
-133% |
|
| Hrusovsky E Kevin |
Chairman, President & CEO |
• • – |
2020-10-01 |
4 |
S |
$34.12 |
$112,126 |
D/D |
(3,286) |
1,037,798 |
|
-133% |
|
| Chaubal Amol |
Chief Financial Officer |
• – – |
2020-10-01 |
4 |
S |
$34.12 |
$3,958 |
D/D |
(116) |
25,377 |
|
-133% |
|
| Madaus Martin D |
|
– • – |
2020-09-29 |
4 |
AS |
$32.49 |
$52,025 |
D/D |
(1,600) |
11,196 |
|
136% |
|
| Madaus Martin D |
|
– • – |
2020-09-29 |
4 |
OE |
$1.93 |
$3,138 |
D/D |
1,600 |
11,338 |
|
- |
|
| Madaus Martin D |
|
– • – |
2020-09-28 |
4 |
AS |
$33.09 |
$52,944 |
D/D |
(1,600) |
11,196 |
|
136% |
|
| Madaus Martin D |
|
– • – |
2020-09-28 |
4 |
OE |
$1.93 |
$3,088 |
D/D |
1,600 |
12,796 |
|
- |
|
| Hrusovsky E Kevin |
Chairman, President & CEO |
• • – |
2020-09-24 |
4 |
AS |
$32.26 |
$64,520 |
D/D |
(2,000) |
1,041,084 |
|
153% |
|
| Duffy David C. |
SVP R&D and CTO |
• – – |
2020-09-17 |
4 |
AS |
$32.43 |
$54,061 |
D/D |
(1,667) |
44,511 |
|
95% |
|
| Madaus Martin D |
|
– • – |
2020-09-17 |
4 |
AS |
$32.43 |
$51,888 |
D/D |
(1,600) |
11,196 |
|
95% |
|
| Madaus Martin D |
|
– • – |
2020-09-17 |
4 |
OE |
$1.93 |
$3,088 |
D/D |
1,600 |
12,796 |
|
- |
|
| Madaus Martin D |
|
– • – |
2020-09-16 |
4 |
AS |
$33.16 |
$53,056 |
D/D |
(1,600) |
11,196 |
|
99% |
|
| Madaus Martin D |
|
– • – |
2020-09-16 |
4 |
OE |
$1.93 |
$3,088 |
D/D |
1,600 |
12,796 |
|
- |
|
| Hrusovsky E Kevin |
Chairman, President & CEO |
• • – |
2020-09-15 |
4 |
AS |
$33.15 |
$116,037 |
D/D |
(3,500) |
1,043,084 |
|
83% |
|
| Madaus Martin D |
|
– • – |
2020-09-02 |
4 |
AS |
$35.08 |
$56,128 |
D/D |
(1,600) |
11,196 |
|
112% |
|
| Madaus Martin D |
|
– • – |
2020-09-02 |
4 |
OE |
$1.93 |
$3,088 |
D/D |
1,600 |
12,796 |
|
- |
|
| Mattoon Dawn |
Sr. VP, Research Products |
• – – |
2020-09-01 |
4 |
S |
$34.91 |
$5,760 |
D/D |
(165) |
31,662 |
|
-92% |
|
| Chaubal Amol |
Chief Financial Officer |
• – – |
2020-09-01 |
4 |
S |
$34.91 |
$4,189 |
D/D |
(120) |
25,493 |
|
-92% |
|
| Hrusovsky E Kevin |
Chairman, President & CEO |
• • – |
2020-09-01 |
4 |
S |
$34.91 |
$118,349 |
D/D |
(3,390) |
1,046,584 |
|
-92% |
|
| Madaus Martin D |
|
– • – |
2020-09-01 |
4 |
AS |
$35.37 |
$56,592 |
D/D |
(1,600) |
11,196 |
|
92% |
|
| Madaus Martin D |
|
– • – |
2020-09-01 |
4 |
OE |
$1.93 |
$3,088 |
D/D |
1,600 |
12,796 |
|
- |
|
| Fry John J |
General Counsel & Secretary |
• – – |
2020-09-01 |
4 |
S |
$34.91 |
$5,167 |
D/D |
(148) |
31,370 |
|
-92% |
|
| Roskey Mark T. |
SVP, Commercial & Accelerator |
• – – |
2020-09-01 |
4 |
S |
$34.91 |
$3,317 |
D/D |
(95) |
21,371 |
|
-92% |
|
690 Records found
|
|
Page 14 of 28 |
|
|
0.05 (0.28%) 
